Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Diabetes Medications: Two Better Than One


Diabetes Medications: Two Better Than One

(ePharmaNews) – Combining "Metformin" and "Rosiglitazone" is the most effective treatement for Type-II diabetic teenagers between 10 and 17 year-old, a new study says.

The longer a patient struggles with diabetes the more severe the complications will be, which means diabetic teenagers are the poorest when it comes to the outcome.

Metformin is the standard treatment for those patients, and is the only oral medication approved by FDA.

The researchers argue that their study is the largest of its kind, and the most reliable in comparing the efficacy of different protocols.

“The results suggest that even in youth who appear to have mild type 2 diabetes, early aggressive intervention is necessary to achieve the control needed to prevent the devastating health consequences of type 2 diabetes, such as coronary artery disease, stroke, kidney and eye disease and nerve damage,” Says Neil H. White, MD, professor of pediatrics and of medicine and director of the Pediatric Clinical Research Unit and a diabetes specialist at St. Louis Children’s Hospital “The impact of these health consequences is clear in adults, but when they manifest at a younger age the personal and societal impact will be even greater.”  

The study included 700 persons aged between 10 and 17 who had type-II diabetes within the previous two years. The participants were divided into three groups, Metformin, Metformin plus Rosiglitazone, and Metformin plus life-style modifications like exercises and losing weight.

Upon follow-up, researchers found that Metformin alone failed in maintaining an acceptable blood level of glucose in half of the participants, and Metformin plus lifestyle modifications failed in 46%, while the Metformin and Rosiglitazone group failed only in 39% of the participants.

“The continued follow-up of these subjects will be an important component of determining the long-term impact of diabetes-related complications and heart disease and the benefits and risks of early intervention,” White says.

The study was published yesterday, April, 29th in NEJM.


اضغط هنا للقراءة باللغة العربية

Prepared by: Mohammed Kanjo
Translated by: Awss Zidan


Source :

ePharmaNews






Other Comments

Add a comment

You must sign in to use this servcie

Username:
Password:


facebook comments

Forgot your password


sign up

Consultants Corner

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details